BOVN.F Stock Overview A clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
BioInvent International AB (publ) Competitors Price History & Performance
Summary of share price highs, lows and changes for BioInvent International Historical stock prices Current Share Price SEK 4.70 52 Week High SEK 6.63 52 Week Low SEK 2.98 Beta 0.48 1 Month Change 0% 3 Month Change n/a 1 Year Change n/a 3 Year Change n/a 5 Year Change n/a Change since IPO 1.08%
Recent News & Updates
Bioinvent International AB Appoints Ashley Robinson as SVP Strategy & Finance to Lead U.S. Expansion Dec 03 BioInvent International AB (publ) to Report Q3, 2025 Results on Oct 29, 2025
Bioinvent and Transgene’S Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase 1/2A Trial in Solid Tumors That Failed Previous Treatments Sep 16
Bioinvent International AB Announces the Enrollment of the First Patient in Triple Combination Arm of Phase 1/2A Study, Bi-1206, Rituximab and Calquence(R) for the Treatment of Non-Hodgkin's Lymphoma Sep 12 Bioinvent Announces Additional Positive Efficacy Data with Single Agent BI-1808 from the Phase 2a anti-TNFR2 program
BioInvent Receives Notice of Allowance from USPTO for BI-1910 Patent Application Jul 30 See more updates
Bioinvent International AB Appoints Ashley Robinson as SVP Strategy & Finance to Lead U.S. Expansion Dec 03 BioInvent International AB (publ) to Report Q3, 2025 Results on Oct 29, 2025
Bioinvent and Transgene’S Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase 1/2A Trial in Solid Tumors That Failed Previous Treatments Sep 16
Bioinvent International AB Announces the Enrollment of the First Patient in Triple Combination Arm of Phase 1/2A Study, Bi-1206, Rituximab and Calquence(R) for the Treatment of Non-Hodgkin's Lymphoma Sep 12 Bioinvent Announces Additional Positive Efficacy Data with Single Agent BI-1808 from the Phase 2a anti-TNFR2 program
BioInvent Receives Notice of Allowance from USPTO for BI-1910 Patent Application Jul 30
Bioinvent International AB Presents Poster Highlighting Model-Informed Early Clinical Development of Anti-TNFR2 Agent BI-1808 At PAGE 2024 Jun 26
BioInvent International Gains Patent for BI-1808 in China Jun 25 BioInvent International AB Presents Promising Clinical Efficacy and Safety for Anti-Tnfr2 Agent BI-1808 At Asco 2024
Bioinvent to Present Additional Promising Phase 1/2A Data At EHA 2024 for BI-1206 with rituximab in NHL May 16 BioInvent International AB (publ) to Report Nine Months, 2024 Results on Oct 31, 2024
BioInvent International AB (publ), Annual General Meeting, May 03, 2024 Mar 28
BioInvent International AB (publ) to Report Fiscal Year 2023 Results on Feb 22, 2024 Feb 21
BioInvent International AB (publ) Presents Positive First Clinical Data on Anti-FcyRIIB Antibody BI-1607 Dec 06
Bioinvent Enrolls First Patient in Phase 1/2A Clinical Trial with TNFR2 Antibody BI-1910 Dec 05
BioInvent Presents Positive Data at SITC from Clinical Phase 1/2a Trial of BI-1808 as Single Agent Nov 04
BioInvent Presents Preclinical Data at SITC Providing Clear Evidence of the Potential of Anti-TNFR2 Antibody BI-1910 Nov 01
Bioinvent International AB Recruits First Patient in Single Agent Phase 2a Part of its Phase 1/2a Trial of its First-in-Class Anti-TNFR2 Antibody BI-1808 in Advanced Malignancies Sep 22
BioInvent International AB Initiates Subcutaneous Arm of Phase 1/2 Trial with BI-1206 in Solid Tumors Sep 08
BioInvent International AB (publ) Reports Strong Interim Safety Data and Early Signs of Efficacy in Phase 1/2a Trial with Anti-TNFR2 Antibody BI-1808 in Advanced Malignancies Jun 21
BioInvent International AB Announces Abstract Presentation of BI-1206 At the 17th International Conference of Malignant Lymphoma 2023 Jun 13
BioInvent International AB Announces Additional Efficacy Data from Intravenous Part of Phase 1/2 Trial with BI-1206 in Solid Tumors Jun 08
BioInvent Ready for Combination Studies with BT-001 Jun 07
BioInvent International AB (Publ) Appoints of Ingunn Munch Lindvig as Senior Vice President Regulatory Affairs May 24 BioInvent International AB (publ), Annual General Meeting, Apr 27, 2023
Bioinvent International AB Provides Update on Its Clinical and Pre-Clinical Pipeline, Including an Update on Its Lead Drug Candidate, the Novel Anti-Fc?RIIB Antibody Bi-1206 Dec 09
BioInvent International AB (publ) Receives FDA IND Approval for Anti-FcyRIIB Antibody BI-1607 Nov 18
BioInvent International AB (publ) Completes Dose Escalation Part of the Phase I/IIa Study with Anti-TNFR2 Drug Candidate BI-1808 Sep 09
CASI Pharmaceuticals and BioInvent Announces Dosing of First Patient in BI-1206 Phase 1 Clinical Trial for the Treatment of Relapsed/Refractory Non-Hodgkin's Lymphoma in China Sep 08 BioInvent International AB (publ) to Report Q2, 2023 Results on Aug 30, 2023 BioInvent International AB (publ) to Report Q1, 2023 Results on Apr 26, 2023
BioInvent International AB (publ) Enrolls First Patient in Phase 1/2A Trial of Bi-1607 in HER2 Positive Solid Tumors Aug 02 Shareholder Returns BOVN.F US Biotechs US Market 7D 0% 0.2% -0.2% 1Y n/a -4.7% 25.6%
See full shareholder returns
Return vs Industry: Insufficient data to determine how BOVN.F performed against the US Biotechs industry .
Return vs Market: Insufficient data to determine how BOVN.F performed against the US Market .
Price Volatility Is BOVN.F's price volatile compared to industry and market? BOVN.F volatility BOVN.F Average Weekly Movement n/a Biotechs Industry Average Movement 11.0% Market Average Movement 6.3% 10% most volatile stocks in US Market 18.3% 10% least volatile stocks in US Market 3.1%
Stable Share Price: BOVN.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BOVN.F's volatility change over the past year.
About the Company BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 in solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma.
Show more BioInvent International AB (publ) Fundamentals Summary How do BioInvent International's earnings and revenue compare to its market cap? BOVN.F fundamental statistics Market cap US$249.15m Earnings (TTM ) -US$3.84m Revenue (TTM ) US$27.21m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) BOVN.F income statement (TTM ) Revenue SEK 295.46m Cost of Revenue SEK 0 Gross Profit SEK 295.46m Other Expenses SEK 337.13m Earnings -SEK 41.66m
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Oct 27, 2022
Earnings per share (EPS) -0.64 Gross Margin 100.00% Net Profit Margin -14.10% Debt/Equity Ratio 0%
How did BOVN.F perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2022/10/26 21:20 End of Day Share Price 2022/07/29 00:00 Earnings 2022/06/30 Annual Earnings 2021/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources BioInvent International AB (publ) is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Morten Larsen ABG Sundal Collier Camilla Oxhamre Carnegie Investment Bank AB Mattias Häggblom Danske Bank
Show 6 more analysts 